Introduction
Polycyclic aromatic hydrocarbons (PAHs), a group of chemicals released into the environment primarily as a result of incomplete fuel combustion, comprise a number of carcinogenic components. For this reason and because of their universal presence in the environment, the impact of PAHs on human health has been of worldwide concern (1) (2) (3) (4) (5) .
Carcinogenic PAHs are metabolised to electrophilic species that react with DNA. The resulting DNA adducts initiate processes that result in cancer development. The prototypical PAH, benzo[a]pyrene (BP), gives rise to multiple DNA adducts of guanine and adenine. However, one major adduct formed in vivo, the r7,t8, t9-trihydroxy-c-10-(N 2 deoxyguanosyl)-7,8,9,10-tetrahydro-benzo[a]pyrene (BPdG), is thought to make critical contributions to cellular events leading to carcinogenesis (6, 7) . PAH-DNA adducts may serve as integrated biomarkers of PAH exposure, reflecting the overall impact of chronic exposure, individual metabolic capacity and DNA repair (8) (9) (10) (11) (12) . In addition, they can be biomarkers of cancer risk (13) (14) (15) (16) (17) .
The ability to measure PAH-DNA adducts in large-scale human studies would seem critical to exposure evaluation and for human cancer risk analysis. The two most commonly used assay methods, 32 P-postlabelling (18) and competitive immunoassays utilising antisera elicited against DNA modified with BP (19) , have advantages but also disadvantages that hamper their use in such studies. 32 P-postlabelling is highly sensitive, able to detect a few adducts in 10 10 nucleotides using 1 lg of DNA, but for the analysis of DNA from environmentally exposed humans has very low chemical specificity. The procedure is labour intensive and uses 32 P radioisotope. Competitive enzyme-linked immunoabsorbent assays (ELISA), on the other hand, recognise only PAH-DNA adducts and has the potential for high throughput. However, competitive ELISA-based immunoassays typically require 50-150 lg of total DNA per sample, an amount that may not be easily available in many studies.
Here, we report the development and validation of a new direct ELISA with a chemiluminescence end point, the BPDE-DNA sandwich chemiluminescence immunoassay (BPDE-DNA SCIA). For the detection of PAH-DNA adducts in human samples, this assay has all the advantages of the BPDE-DNA chemiluminescence immunoassay (CIA) (20) and, in addition, requires only 11 lg of DNA for duplicate analysis (including 1 lg which compensates inaccuracies during pipetting), indicating suitability for large-scale population studies. An adaptation of a recently reported analogous assay for O 6 -methylguanine (O 6 -meG) (21) , the BPDE-DNA SCIA employs DNA fragments (Mspl restriction) containing �1 PAH-DNA adduct residue. A rabbit antiserum elicited against DNA modified with BPDE (22) selectively transfers the adduct-containing fragments from the bulk of the DNA to a solid surface. For the final detection, monoclonal anti-single-stranded (ss) DNA antibody is utilised in combination with a chemiluminescence end point. The high ratio of normal nucleotides to adducts in each fragment serves to enhance the signal and sensitivity while maintaining proportionality with the PAH-DNA adducts.
It has been previously shown that the antiserum cross reacts with DNA adducted with other PAHs (23) and hence, when analysing human DNA samples, the signal obtained reflects a composite exposure to a mixture of PAHs and therefore the presence of adducts of a variety of PAHs (24) .
In 
Materials and methods

Biochemicals
The anti-BPDE-DNA rabbit antiserum was from rabbit #33 bleed 8/2/1978 and was elicited against DNA modified in vitro with BPDE, where the only measurable adduct was the BPdG (22) . BPDE was custom synthesised by Dr Albrecht Seidel at Biochemisches Institut für Umweltcarcinogene, Prof. Dr Gernot Grimmer-Stiftung, Grosshansdorf, Germany. All other biochemicals were from Sigma Chemical Co. (St Louis, MO, USA) unless otherwise stated.
Purification of DNA
The purification of DNA from HepG2 cells, human blood mononuclear cells and mouse tissues was performed with Qiagen Blood & Cell Culture DNA purification kits, according to the manufacturer's instructions with minor modifications (18, 21) . DNA purified with this method had an average length of 35 000-50 000 bp and an A 260 /A 280 ratio within the range of 1.75-1.85. DNA from MCF-7 cells was purified by three methods: Qiagen columns, traditional phenol/chloroform/isoamyl alcohol extraction (25) and the salting out method for protein precipitation and DNA isolation (26) .
Cell culture
HepG2 cells were grown in Dulbecco's minimal essential medium (Gibco) (containing glucose 4.5 g/l, L-glutamine and pyruvate) supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin (Gibco), at 37°C in a humidified incubator with 5% CO 2 . Cells were treated with 0.02-2.00 lM BP and harvested after 24 h for DNA isolation. Pellets of MCF-7 cells, which had been treated in aliquots of 2 Â 10 7 cells with 1 lM BP at 37°C for 24 h, were kindly provided by Dr D.H. Phillips (see Acknowledgments).
Mouse exposures
Male CD2F1 mice, 10 weeks old and weighing 25-30 g (purchased from Charles River Laboratories Italia S. P. A., Italy), were administered single intraperitoneal injections of BP (100 and 200 mg/kg), B[b]F (200 and 400 mg/ kg) and DB[a,h]A (2.5, 5 and 10 mg/kg), in tricaprylin. The animals were sacrificed 14 days after the treatment, the liver tissue was removed and used for DNA extraction by Qiagen mini columns, as described above and subsequent adduct analysis In addition, aliquots of liver DNA's from several mice, treated with BP, were pooled and served as a quality control standard (QC) in all the ELISA assays.
Standard BPDE-modified DNA (BPDE-DNA) Samples of DNA modified to different levels with BPDE were prepared by incubating HeLa cell DNA (20 mg; 1 mg/ml in 0.1 M Tris-HCl, pH 7.4) overnight in the dark at 37°C with BPDE dissolved in tetrahydrofuran. The final concentrations of BPDE were 100, 25, 10 and 2.5 lg/ml. After repeated extractions with diethyl ether (eight times) and isoamyl alcohol (four times), both saturated with water, the aqueous phase was collected and the DNA was precipitated by adding 2.5 volumes cold ethanol, washed twice with 70% ethanol, dried and redissolved in distilled water. The levels of BPdG adducts were determined by spectrophotometric analysis, using an extinction coefficient for the BPdG adduct at 350 nm of 29 000. The concentrations of the adducted double-stranded DNA samples were calculated assuming that one absorbance unit at 260 nm equals 50 lg/ml. The modification levels of the DNA samples obtained for the concentrations of BPDE mentioned above were 7.00 (0.7%), 1.31 (0.13%), 0.64 (0.064%) and 0.16 (0.016%) adducts per 1000 nucleotides, respectively. The modified DNA samples were sent to the University of Leicester (see Acknowledgments), where they were analysed for BPdG adducts using liquid chromatography-mass spectrometry (LC-MS/MS), and the results obtained were in excellent agreement with the spectrophotometric measurements. The DNA with the lowest level of modification ($1 adduct per 6000 nucleotides) was used for the SCIA standard curves.
PAH-DNA adduct analysis with the BPDE-DNA SCIA The new immunoassay was first developed for O 6 -meG, and details have been described in Georgiadis et al. (21) . In general, the same assay conditions were used for the BPDE-DNA SCIA, but the use of the BPDE-DNA antiserum and the additional steps required optimisation. For the BPDE-DNA SCIA, a 96-well high-binding microtiter plate (Greiner Labortechnik, Germany) was coated with 100 ll goat anti-rabbit IgG, species absorbed for minimum cross reactivity (Millipore Inc., Billerica, MA, USA), diluted 1:300-fold in coating buffer (Na 2 CO 3 0.015 M, NaHCO 3 0.035 M; pH: 9.6) and incubated overnight at 4°C. After washing three times with water, non-specific binding was blocked by adding to the wells 310 ll 0.25% casein (I-block; Tropix, Bedford, MA, USA) in phosphate-buffered saline with 0.5% Tween (PBST) for 1.5 h at 37°C, followed by two cycles of washing with PBST.
Standard adducted DNA, containing 0.16 BPdG adducts per 1000 nucleotides, and the unknown DNA samples (duplicates of 5.5 lg each; 11 lg in total) were exhaustively digested with MspI (10 units/lg DNA) (New England Biolabs Inc.) by overnight incubation at 37°C in a total volume of 55 ll in 50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl 2, 1 mM dithiothreitol; pH 7.9. The DNA was subsequently denatured by heating to 95°C for 10 min, snap frozen in liquid nitrogen and then allowed to thaw on ice. Subsequently, an equal volume of anti-BPDE-DNA rabbit antiserum (diluted 1:12 500 in 2ÂPBST, 0.5% casein) was added to the DNA and the mixture (110 ll in total) was incubated at 37°C for 1.5 h in a shaking water bath. One hundred microlitres of each DNA plus antiserum mixture (containing 10 lg of DNA) was then transferred into triplicate microtiter plate wells and incubated for 1.5 h at room temperature, followed by five cycles of washing with PBST. Two sequential steps then followed: (i) addition of 100 ll mouse anti-ss DNA antibodies, semi-purified from culture cell supernatant (Millipore Inc.) diluted 100-fold with PBST, 0.25% casein and (ii) addition of purified goat antimouse-IgG antiserum conjugated with alkaline phosphatase, with minimum species cross reactivity, (Biolegend, San Diego, CA, USA) diluted (1:500) in PBST containing 0.25% casein. Each step was followed by five cycles of washing with PBST. Finally, two additional washing cycles with Tris buffer (20 mM Tris-1 mM MgCl 2 , pH 9.5) were performed. One hundred microlitres CDP-Star containing Emerald II enhancer (Tropix, Bedford, MA, USA) was then added to the wells, the plates were incubated at room temperature for 30 min and luminescence was read using a Safire II Microplate Luminometer (TECAN) at 542 nm. The levels of PAH-DNA adducts in the unknown samples were calculated by comparison with a BPDE-DNA standard curve (common range of standard: 0.1-2 fmol BPdG adducts per well), constructed for each microwell plate employed on each assay occasion. In addition, a sample of BP-treated mouse liver DNA of known adduct content (measured also by LC-MS-MS) was used in triplicate with each microtiter plate as a quality control standard.
Determination of bulky DNA adducts by 32 
P-postlabelling
The levels of bulky DNA adducts were determined by the regular 32 P-postlabelling procedure, as described in detail previously (18) .
Samples from mother-infant pairs
Samples of blood mononuclear cells were collected from subjects (40 mothers and paired 40 newborns) participating in a mother-newborn child biobank in Copenhagen (27) , a pilot study within the Newborns and genotoxic exposure risks (NewGeneris) project (28) . Ethical clearance for the study was provided by the Danish Ethics Committee, and the project was reviewed and approved prior to initiation by the Ethics Committee of the Capital Region of Denmark and the Danish Data Protection Agency (J. Nr. H-KF-01-327603; J. Nr. 2007-41-0415). Venous peripheral blood from the mother and cord blood of her newborn child was collected at delivery into heparinised vacutainer tubes. Samples were processed within 1 h to obtain mononuclear cells, which were stored at À80°C until transfer to the assay laboratory.
Statistical methods
Tests used for statistical analysis included: (i) analysis of variance for comparisons of DNA adduct levels between DNA samples purified with different protocols; (ii) independent and paired Student's t-tests to evaluate the difference of the adduct levels measured by SCIA and 32 P-postlabelling; (iii) the Mann-Whitney and two-tailed Wilcoxon tests for assessing the difference of DNA adduct levels between maternal and cord blood and, (iv) Spearman correlation tests for calculating the correlation between DNA adduct levels P. Georgiadis et al. measured in maternal and cord blood or samples analysed by different methods. For calculations of the levels of DNA adducts measured by SCIA in the human samples, samples with non-detectable adducts were assigned a value half way between zero and the limit of detection.
Results
Standard curves and assay precision
In order to minimise the between-assay variation, each microtiter plate contained a standard curve (see Materials and methods) constructed by mixing different amounts of standard DNA of known BPdG adduct content with adduct-free HeLa DNA. The level of modification of the standard DNA ($1 adduct per 6000 normal nucleotides) ensured that the proportion of MspI digestion fragments with more than one adduct would be negligible. The signal-to-noise ratio of the assay continued to increase throughout the range of decreasing mouse anti-ss DNA antiserum dilutions tested (results not shown), and for this reason, final dilutions were adopted taking into consideration material availability and cost. As shown in Figure 1A , the luminescence signal obtained was linearly related (r 2 5 0.99) to the amount of BPDE-DNA adducts added (range: 0.05-0.5 fmol) and the coefficient of variance (CV) was 2.5%. Linearity is retained up to 2 or 3 fmols and the curve deviates from linearity (negatively) only above this concentration due to the instrument upper limit for signal detection (results not shown). Despite this excellent reproducibility, the absolute levels of the chemiluminescence signals showed significant day-to-day variation, which necessitated the construction of a standard curve for each experiment. The mean slope-to-intercept ratio of 10 standard curves, constructed over a period of 1 month, was 0.82 AE 0.22 (SD) fmol À1 , demonstrating consistent and stable assay response. The mean limit of detection (3Â SD of the signal of unmodified carrier DNA) of the above-mentioned standard curves was 42.0 AE 17.8 (SD) attomole. Most importantly, a QC sample of BPtreated DNA (see Materials and methods), which was included in all the above analyses, gave a mean adduct level of 32.2 adducts per 10 8 normal nucleotides ( Figure 1B ) with a CV of 10.5%. The same sample was also analysed by LC-MS-MS and the BPdG adduct levels were found to be 36.2 adducts per 10 8 nucleotides, in excellent agreement with the mean value determined by SCIA.
In traditional competitive ELISAs, the accuracy of the measurement of the adduct levels is greatly dependent on the density of the adducts in the standard DNA, something that necessitates the latter being adducted at a similar level to the test samples (29) . In the SCIA, the digestion of the DNA to fragments containing no more than one adduct is anticipated to overcome this necessity. In order to test this hypothesis and further validate the assay, we constructed two standard curves on the same plate, one using our standard DNA, which contained 1 adduct per 6000 nucleotides and a second one using DNA modified at a level of 1.1 adducts per 10 Sensitive immunoassay for PAH-DNA adducts suitable for molecular epidemiology DNA per well on assay sensitivity was evaluated by examining the variation of the intensity of the signal generated by a constant amount of BPdG (0.5 or 1.0 fmol) in the presence of 1-10 lg DNA per well. No significant variation in luminescence signal between 1 and 10 lg DNA was found ( Figure 1D ) and subsequently, when using 5 or 10 lg of DNA per well, the limit of detection was estimated as $3 or 1.5 adducts per 10 9 nucleotides, respectively.
Assay validation: dynamic range, influence of DNA isolation method comparison with 32P-postlabelling Using DNA isolated from HepG2 cells treated for 24 h with 0.02-2.0 lM BP, the BPdG adducts measured by SCIA were found to be linearly related to the BP concentrations (Figure 2) , indicating that the dynamic range of the assay is at least two orders of magnitude. The highest dose of BP gave rise to 22 BPdG adducts per 10 8 nucleotides while the lowest dose to 0.27 BPdG per 10 8 nucleotides. Experiments were conducted to evaluate the accuracy and reproducibility of the new assay, as well as the influence of the DNA isolation method on the measured adduct levels, and to compare the adduct levels measured in the same DNA by BPDE-SCIA and 32 P-postlabelling (Table I) . For this purpose, MCF-7 cells were treated with 1 lM BP for 24 h, harvested and separated into aliquots which were used to isolate DNA using three different methods: Qiagen columns, phenolchloroform extraction and salting out. For each DNA isolation method, three different DNA samples were analysed twice (SCIA) or three times ( 32 P-postlabelling) on consecutive days.
SCIA showed better reproducibility than 32 P-postlabelling, and the DNA adduct measurements by SCIA showed good reproducibility for samples analysed multiple times on the same day or on different days (Table I ). In addition, unlike 32 Ppostlabelling, SCIA allowed us to analyse up to 70 samples/ week per person and was proved to be a high-throughput method, when fully automated.
There was no significant difference in DNA adduct value by SCIA when the DNA was prepared by any of the three methods. The levels of BPdG adducts measured by SCIA were 30-60% (depending on the DNA extraction method) lower than those measured by 32 P-postlabelling. However, the mean SCIA adduct values measured on different days in the DNA samples prepared by Qiagen and salting out were highly correlated with those obtained by 32 P-postlabelling, either when examined independently or when examined pairwise (P values in Table I ). Although the SCIA gave consistently lower adducts than the 32 P-postlabelling assay, it is probable that the major adduct in these cells was BPdG, and this is likely why the two assays showed a good correlation.
Assay specificity
The anti-BPDE-DNA antiserum employed in our assay was elicited against DNA modified with BP, but it has been shown to recognise and cross react with DNA modified with a series of carcinogenic PAHs in addition to BP (23) . Therefore, because humans are exposed to mixtures of environmental PAHs, values for human samples, assayed using this antiserum with a BPDE-DNA standard curve, will be semi-quantitative. In addition, it is important to know as much as possible about the cross reactivity of the antiserum and two common PAHs %CV1 refers to the within-day coefficient of variance for adduct levels measured by either method in independently extracted DNA samples, while %CV2 refers to the inter-day coefficient of variance of the same samples analysed twice or three times on different days; P1: P value for independent t-test for the inter-day mean adducts levels obtained by the two methods; P2: P value for paired t-test. compared to 30-60% reported above for adducts produced in MCF7 cells, may be explained on the basis of the known ability of the liver to form multiple types of DNA-binding products that may not cause similar responses in SCIA.
DNA adducts determined in maternal peripheral and infant cord blood mononuclear cells Mononuclear cell DNA extracted from peripheral blood of mothers and cord blood from their infants (n 5 40 matched pairs) was analysed for DNA adducts. The standard curves were constructed using 5 lg DNA containing 0.1-2 fmol BPdG adducts per well since most samples (5 lg per well) had detectable adduct levels within that range. By BPDE-DNA SCIA, the mean maternal and cord blood adduct levels were 1.41 AE 0.93 (mean AE SD) and 1.13 AE 0.99 adducts per 10 8 nucleotides, respectively ( Figure 4A ), while the corresponding median values were 1.32 and 0.93 adducts per 10 8 nucleotides, respectively. The mean maternal adduct levels were statistically significantly higher than those of cord blood (P 5 0.04; twotailed Wilcoxon test). Three maternal and eight cord blood DNA samples, which fell below the detection limit (3 adducts per 10 9 nucleotides; 5 lg DNA/well), were assigned a value of 1.5 adducts per 10 9 nucleotides (half way between zero and the limit of detection).
The levels of bulky DNA adducts measured by 32 Ppostlabelling were $10-fold higher than those measured by BPDE-DNA SCIA for both maternal and cord blood samples ( Figure 4B ). Mean maternal and cord blood bulky DNA adduct values were 11.5 AE 9.0 (mean AE SD) and 10.7 AE 9.1 adducts per 10 8 nucleotides, respectively (P . 0.05), while the corresponding median values were 8.4 and 7.2 adducts per 10 8 nucleotides, respectively. There was no correlation between the DNA adduct levels measured by the two methods for either the maternal or the cord DNA samples (Figure 4C  and D) . However, a comparison of maternal and cord blood samples measured by the same assay showed significant correlations between maternal and cord blood adducts measured by each of the two methods (Figure 5A and B; Spearman correlation coefficient 5 0.66 and 0.60, respectively; P , 0.001 for both).
Discussion
Numerous methods have been developed for the detection and measurement of PAH-derived DNA adducts, including high pressure liquid chromatography (HPLC) (30, 31) , and MSbased methods, which allow for chemical-specific adduct identification and quantitation (32, 33) . Typically, structurespecific methods require so much DNA that they cannot be applied to population studies involving general environmental exposures (e.g. HPLC-MS-MS requires 100 lg of DNA for a single analysis). For this reason, 32 P-postlabelling (34), immunoassays (19) and immunohistochemistry (24) have been employed more widely in such studies. 32 P-postlabelling for PAH adducts analysis is very sensitive (the limit of detection is commonly 1 adduct per 10 9 nucleotides using 10 lg DNA per reaction), but it lacks chemical specificity and the majority of the adducts detected are largely unknown. In addition, the procedure is time consuming, labour intensive and has low resolution. The 'classic' competitive ELISA assay for PAH-DNA adducts was reported to have a sensitivity of $4 adducts per 10 8 nucleotides using 25-35 lg of DNA per well. However, .200 lg of DNA are required per sample, due to the high background and variability of the signal. The related competitive dissociation-enhanced lanthanide fluoro-immunoassayassay (DELFIA) increased the sensitivity to ,1 adduct per 10 8 nucleotides without reducing however the total quantity of DNA required. A further increase in the sensitivity-approaching that of 32 P-postlabelling-was achieved by the CIA (20) , but the requirements for DNA remained substantial ($50 lg per sample). Therefore, there is still a need for DNA adduct assays of improved sensitivity and throughput, which can be employed in large-scale population studies, and for which only limited amounts of DNA are available. We have recently developed a direct sandwich ELISA for the detection and quantification of O 6 -methylguanine (O 6 -meG SCIA) in human samples. This type of assay combines high sensitivity and high throughput (21) , exhibits a linear dose-response relationship over a wide range of adduct levels and can, in principle, be Sensitive immunoassay for PAH-DNA adducts suitable for molecular epidemiology adapted for the quantification of different DNA adducts if suitable anti-adduct antisera and appropriate standard adducted DNA are available.
Here, we have described the development, validation and pilot application of a similar assay for PAH-DNA adducts. The BPDE-DNA SCIA provides substantially improved sensitivity as compared to the BPDE-DNA competitive ELISAs and improved throughput as compared to 32 P-postlabelling and enables the detection of BPdG or PAH-DNA adducts in the majority of samples from environmentally exposed subjects. Duplicate analyses can be obtained with 11 lg DNA (allowing for 1 lg to be consumed during sample processing). The method is based on exhaustive restriction digestion of DNA to fragments ,6000 bp in length, a size expected to contain no more than a single adduct residue. The adduct-containing fragments are bound to a solid surface with BPDE-DNA antibodies, and the plate-immobilised DNA fragments are detected by incubation with anti-ss DNA secondary antisera with alkaline phosphatase and a chemiluminescence end point.
The BPDE-DNA SCIA has several advantages. After optimisation, an assay limit of detection of 0.05 fmol per well was achieved, which corresponds to 3 adducts per 10 9 nucleotides when using 5 lg DNA per well. Up to 10 lg DNA per well does not affect assay performance, and sensitivity can be increased with higher concentrations of anti-DNA antiserum. The assay exhibits satisfactory accuracy and reproducibility characteristics. Analysis of DNA samples from cells treated with different doses of BP gave results in good agreement with those previously reported by others (35) and indicated that the dynamic range of the assay covers at least two orders of magnitude. Standard curves obtained with BPdG-DNA containing 1 adduct per 6000 nucleotides, as measured by spectrophotometry, and 1.1 adduct per 10 6 nucleotides as measured by LC-MS-MS were almost superimposable, confirming our hypothesis that restriction digestion of the DNA to fragments containing no more than a single adduct residue should eliminate the requirement, common for competitive ELISAs, for a standard DNA modified at the same level as the test samples (29) .
The influence of the method of DNA isolation as well as the intra-and between-day variability of the assay was evaluated. Comparable results were obtained with DNA isolated by phenol extraction, Qiagen columns or salting out. The withinday reproducibility of the assay for independently extracted DNAs was higher, and the inter-day variability significantly lower than reported values for previously employed competitive immunoassays (20) . The adduct levels as measured by SCIA in MCF-7 cells treated with BP were compared with those obtained by 32 P-postlabelling and found to be 30-60% lower (depending on the DNA extraction method). It is possible that some adducts detected by 32 P-postlabelling are not recognised by the BPDE-DNA SCIA (36) . Nevertheless, a very strong correlation was observed between the adduct levels obtained by the two methods.
The chemical specificity of immunoassays is limited by the recognition characteristics of the antisera employed. The antiadduct antiserum was raised against BPDE-modified DNA and is known to also recognise adducts produced by other carcinogenic PAHs (22) . In order to further characterise the specificity of this antiserum, we analysed DNA samples isolated from the livers of mice exposed to two additional PAHs, DB[a,h]A and B[b]F and found strong cross reactivity with the BPDE-DNA antiserum in the SCIA. In addition, we analysed the same samples by 32 P-postlabelling and found that the absolute levels measured by SCIA were substantially lower than those measured by 32 P-postlabelling. The reduced capacity of SCIA to detect DNA adducts of DB[a,h]A and B[b]F reflects the reduced avidity of the anti-BPDE-DNA antiserum for these PAH-DNA adducts. This finding confirms the broad compound class specificity of the BPDE-DNA SCIA and emphasises the fact that DNA samples from environmentally exposed humans should be considered to provide a semi-quantitative aggregate measure of PAH-DNA adduct formation.
The new assay is currently being employed in the NewGeneris project (28) . Here, we report measurements of the levels of PAH-DNA adducts by the new method and of bulky DNA adducts by 32 P-postlabelling from buffy coats of 40 pairs of maternal and cord blood samples. The donors were nonsmoking women living in Denmark and were likely to have experienced exposure to very low levels of PAHs. Using SCIA, the adduct levels observed were of the order of 1 adduct per 10 8 nucleotides comparable to those previously reported with the use of other immunoassays (13, 20, 37) . On the other hand, the adduct levels measured in the same samples by 32 Ppostlabelling were of the order of 10 adducts per 10 8 nucleotides, close to those reported in some studies (38) but significantly higher (10-fold) than those of other studies which involved exposure to high levels of air pollution (39, 40) . In a study utilising both methods for adduct detection, the levels obtained by ELISA were 2-to 4-fold lower than those obtained by postlabelling (41) , although other studies reported comparable values for either assays (42) . It should be noted that the majority of previous human studies utilised samples of DNA purified by phenol extraction, unlike our study where they were purified by Qiagen columns. Kovács et al. (18) used both phenol extraction and Qiagen columns for DNA purification prior to the measurement of bulky DNA adducts from lymphocytes of environmentally exposed individuals and MCF-7 cells treated with BPDE. They found slightly higher bulky adduct levels in MCF-7 cells and several fold higher levels in the human samples when the Qiagen columns were used for DNA purification. These results indicate that our knowledge of the nature of the various bulky DNA adducts and of their stability during the different DNA isolation procedures is limited and underline the need for fully standardised methods to obtain comparable results.
The adduct levels measured with either assay in maternal and the respective cord blood DNA were quantitatively comparable and closely correlated. On the other hand, there was no correlation between the DNA adduct levels determined by SCIA and 32 P-postlabelling, with SCIA yielding substantially lower values. Lack of correlation in the levels of BPDE-DNA adducts in PAH-exposed study populations, measured by ELISA, DELFIA or CIA immunoassays, and 32 P-postlabelling have also been reported in the past (43, 44, 38) . Most recently, Pratt et al. (45) utilised a similar to ours anti-adduct antiserum to determine in placentas PAH-DNA adduct levels semi-quantitatively by immunohistochemistry and bulky DNA adducts by 32 P-postlabelling and found no correlation between the levels of the two types of adducts. The lack of correlation between adduct levels measured by immunochemical assays and 32 P-postlabelling is in concordance with our findings and probably reflects (i) the variable ability of antisera raised against a particular type of PAH-DNA adduct to recognise adducts of other PAHs and (ii) the fact that probably only some of the bulky hydrophobic DNA adducts detected by 32 P-postlabelling are related to PAHs. In summary, this report demonstrates the practical utility of a new direct sandwich ELISA for PAH-DNA adducts characterised by increased sensitivity, capable of detecting this type of DNA damage in a large proportion of DNA samples of humans suffering low environmental exposures. The small amount of material required (just .10 lg DNA for duplicate analysis) and its throughput (70 samples/week per person) makes this assay suitable for use in the context of studies utilising samples from biorepositories. Sensitive immunoassay for PAH-DNA adducts suitable for molecular epidemiology
